
AKRO
Akero Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
47.490
Open
47.490
VWAP
--
Vol
3.76K
Mkt Cap
3.79B
Low
47.490
Amount
--
EV/EBITDA(TTM)
--
Total Shares
69.15M
EV
3.13B
EV/OCF(TTM)
--
P/S(TTM)
--
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-1.004
+1.39%
--
--
-0.955
-9.06%
--
--
-0.872
+7.64%
Estimates Revision
Stock Price
Go Up

+4.12%
In Past 3 Month
9 Analyst Rating

47.63% Upside
Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is 70.11 USD with a low forecast of 49.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy

47.63% Upside
Current: 47.490

Low
49.00
Averages
70.11
High
84.00

47.63% Upside
Current: 47.490

Low
49.00
Averages
70.11
High
84.00
BofA
Buy
maintain
$63 -> $64
2025-05-27
Reason
BofA
Price Target
$63 -> $64
2025-05-27
maintain
Buy
Reason
BofA raised the firm's price target on Akero Therapeutics to $64 from $63 and keeps a Buy rating on the shares. Akero's Q1 print was "unsurprisingly quiet," taking a backseat to other updates as FGF21 agonist efruxifermin continues to advance for fatty liver disease, the analyst tells investors in a post-earnings note.
Citi
Buy
downgrade
$80 -> $78
2025-05-13
Reason
Citi
Price Target
$80 -> $78
2025-05-13
downgrade
Buy
Reason
Citi lowered the firm's price target on Akero Therapeutics to $78 from $80 and keeps a Buy rating on the shares. The company reported Q1 earnings after it revealed clinical data from its Phase 2b SYMMETRY trial at the European Association for the Study of the Liver conference last week, the analyst tells investors in a research note. The firm says the detailed data showed that efruxifermin treatment led to improvements on multiple noninvasive measures of liver fibrosis, adding on to 96-week topline liver biopsy data released earlier this year.
Morgan Stanley
Overweight
downgrade
$90 -> $84
2025-05-12
Reason
Morgan Stanley
Price Target
$90 -> $84
2025-05-12
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Akero Therapeutics to $84 from $90 and keeps an Overweight rating on the shares. Q1 results were uneventful, following multiple data updates last week, further confirming robust benefits on fibrosis, while execution across the Phase 3 SYNCHRONY program continues to be on track, the analyst tells investors in a research note. The firm updated its model to reflect the report and recent trends, specifically reducing its initial EFX sales and increasing its outer year sales tot reflect a more conservative view on the timing of a U.S. launch in F5 patients, pending outcomes data.
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$72 → $75
2025-03-03
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$72 → $75
2025-03-03
Maintains
Strong Buy
Reason
UBS
Eliana Merle
Strong Buy
Maintains
$42 → $109
2025-01-31
Reason
UBS
Eliana Merle
Price Target
$42 → $109
2025-01-31
Maintains
Strong Buy
Reason
UBS raised the firm's price target on Akero Therapeutics to $109 from $42 and keeps a Buy rating on the shares. Akero reported "strong" results from the 96-week biopsy data from the Phase 2b SYMMETRY trial of FGF21efruxifermin in metabolic dysfunction-associated steatohepatitis F4s, with efruxifermin 50mg resulting in a 24% effect size in fibrosis improvement over placebo at 96 weeks in a completers analysis, and in an ITT analysis, the effect size was 17%, the analyst tells investors in a research note. The firm still sees potential upside from here, and thinks the updated data is supportive of a significant opportunity for FGF21s as potentially the most potent anti-fibrotic class in MASH.
B of A Securities
Alexandria Hammond
Hold
to
Strong Buy
Upgrades
$35 → $63
2025-01-30
Reason
B of A Securities
Alexandria Hammond
Price Target
$35 → $63
2025-01-30
Upgrades
Hold
to
Strong Buy
Reason
BofA analyst Jason Zemansky upgraded Akero Therapeutics to Buy from Neutral with a $63 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Akero Therapeutics Inc (AKRO.O) is -12.51, compared to its 5-year average forward P/E of -9.02. For a more detailed relative valuation and DCF analysis to assess Akero Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-9.02
Current PE
-12.51
Overvalued PE
-5.07
Undervalued PE
-12.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-6.57
Current EV/EBITDA
-8.18
Overvalued EV/EBITDA
-2.52
Undervalued EV/EBITDA
-10.63
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+34.91%
-80.88M
Operating Profit
FY2025Q1
YoY :
+32.58%
-70.73M
Net Income after Tax
FY2025Q1
YoY :
-0.00%
-0.90
EPS - Diluted
FY2025Q1
YoY :
+92.56%
-67.66M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.9M
USD
27
3-6
Months
6.6M
USD
14
6-9
Months
21.7M
USD
26
0-12
Months
8.8M
USD
22
Bought
0-3
0
0.0
USD
Months
3-6
3
8.8M
USD
Months
6-9
1
9.6M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 117.24% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.4M
Volume
4
6-9
Months
5.9M
Volume
5
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
8
4.1M
Volume
Months
6-9
4
1.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.9M
USD
27
3-6
Months
6.6M
USD
14
6-9
Months
21.7M
USD
26
0-12
Months
8.8M
USD
22
Bought
0-3
0
0.0
USD
Months
3-6
3
8.8M
USD
Months
6-9
1
9.6M
USD
Months
0-12
0
0.0
USD
Months
AKRO News & Events
Events Timeline
2025-06-13 (ET)
2025-06-13
11:49:43
Jefferies sees Akero, Scholar Rock as 'promising' takeover targets

2025-06-09 (ET)
2025-06-09
09:35:15
Akero Therapeutics rumor highlighted in Betaville blog

2025-05-20 (ET)
2025-05-20
13:15:34
Akero Therapeutics up 16% after Street Insider report on sale being considered

Sign Up For More Events
Sign Up For More Events
News
9.0
07-17NASDAQ.COMAstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
4.0
05-27TipRanks3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
8.5
05-20SeekingAlphaAkero surges after report on plans for potential sale
Sign Up For More News
People Also Watch

TSLA
Tesla Inc
322.353
USD
+0.36%

META
Meta Platforms Inc
702.700
USD
+0.39%

NVDA
NVIDIA Corp
177.660
USD
+1.23%

AVGO
Broadcom Inc
301.000
USD
+1.20%

AMZN
Amazon.com Inc
231.480
USD
+0.20%

WMT
Walmart Inc
98.790
USD
+0.47%

AAPL
Apple Inc
210.430
USD
-0.40%

MSFT
Microsoft Corp
512.480
USD
-0.02%

GOOGL
Alphabet Inc
195.790
USD
+0.02%

GOOG
Alphabet Inc
197.100
USD
+0.34%
FAQ

What is Akero Therapeutics Inc (AKRO) stock price today?
The current price of AKRO is 47.49 USD — it has increased 0 % in the last trading day.

What is Akero Therapeutics Inc (AKRO)'s business?

What is the price predicton of AKRO Stock?

What is Akero Therapeutics Inc (AKRO)'s revenue for the last quarter?

What is Akero Therapeutics Inc (AKRO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Akero Therapeutics Inc (AKRO)'s fundamentals?

How many employees does Akero Therapeutics Inc (AKRO). have?
